Synapse Open Synapse
Biology

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial

Nature Biological Sciences · · 30 min read

Signal Transduction and Targeted Therapy - Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase...

Latest from Nature Biological Sciences